These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37752381)

  • 1. Associations between anemia and FGF23 in the CKiD study.
    Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
    Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth-factor 23 and vitamin D are associated with iron deficiency and anemia in children with chronic kidney disease.
    Karava V; Dotis J; Kondou A; Christoforidis A; Taparkou A; Farmaki E; Economou M; Printza N
    Pediatr Nephrol; 2023 Aug; 38(8):2771-2779. PubMed ID: 36862253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
    Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients.
    Limm-Chan B; Wesseling-Perry K; Pearl MH; Jung G; Tsai-Chambers E; Weng PL; Hanudel MR
    Pediatr Nephrol; 2021 Oct; 36(10):3241-3249. PubMed ID: 33903951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
    Agoro R; White KE
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
    David V; Martin A; Isakova T; Spaulding C; Qi L; Ramirez V; Zumbrennen-Bullough KB; Sun CC; Lin HY; Babitt JL; Wolf M
    Kidney Int; 2016 Jan; 89(1):135-46. PubMed ID: 26535997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intact and C-Terminal FGF23 Assays-Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?
    Sharma S; Katz R; Bullen AL; Chaves PHM; de Leeuw PW; Kroon AA; Houben AJHM; Shlipak MG; Ix JH
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4875-85. PubMed ID: 32951052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
    Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
    Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.
    Czaya B; Faul C
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.
    Tsai MH; Leu JG; Fang YW; Liou HH
    Medicine (Baltimore); 2016 Mar; 95(11):e3049. PubMed ID: 26986127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
    Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
    Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
    Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.